2,582 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Wayfinding Financial LLC

Wayfinding Financial LLC purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 2,582 shares of the biopharmaceutical company’s stock, valued at approximately $238,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of GILD. Swedbank AB boosted its holdings in Gilead Sciences by 10.2% during the third quarter. Swedbank AB now owns 2,047,609 shares of the biopharmaceutical company’s stock worth $171,672,000 after purchasing an additional 189,622 shares during the last quarter. Quest Partners LLC increased its stake in Gilead Sciences by 163.4% in the 3rd quarter. Quest Partners LLC now owns 8,400 shares of the biopharmaceutical company’s stock valued at $704,000 after buying an additional 5,211 shares during the last quarter. Pathstone Holdings LLC increased its stake in Gilead Sciences by 0.9% in the 3rd quarter. Pathstone Holdings LLC now owns 101,048 shares of the biopharmaceutical company’s stock valued at $8,472,000 after buying an additional 891 shares during the last quarter. Commerce Bank increased its stake in Gilead Sciences by 10.8% in the 3rd quarter. Commerce Bank now owns 72,494 shares of the biopharmaceutical company’s stock valued at $6,078,000 after buying an additional 7,055 shares during the last quarter. Finally, Citizens Financial Group Inc. RI increased its position in shares of Gilead Sciences by 5.6% in the third quarter. Citizens Financial Group Inc. RI now owns 6,321 shares of the biopharmaceutical company’s stock valued at $530,000 after acquiring an additional 337 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Trading Up 1.1 %

GILD stock opened at $107.08 on Friday. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The company’s 50-day simple moving average is $103.68 and its 200 day simple moving average is $93.75. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $119.96. The company has a market capitalization of $133.35 billion, a PE ratio of 289.41, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be given a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a yield of 2.95%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s dividend payout ratio is currently 854.05%.

Analyst Upgrades and Downgrades

GILD has been the topic of a number of recent research reports. Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a “hold” rating to a “buy” rating and lifted their target price for the company from $80.00 to $120.00 in a research report on Tuesday, February 18th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $80.00 price target on shares of Gilead Sciences in a research report on Wednesday, December 11th. DZ Bank upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 target price on the stock in a report on Thursday, February 13th. Wells Fargo & Company boosted their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. Finally, Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a report on Wednesday, February 12th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average target price of $104.52.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 17,929 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the sale, the chief financial officer now directly owns 169,061 shares in the company, valued at $19,977,938.37. This represents a 9.59 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In the last three months, insiders have sold 302,785 shares of company stock valued at $30,503,250. 0.29% of the stock is owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.